Moderna (NASDAQ:MRNA) reshuffled its board adding ex-Biogen CFO Michael McDonnell as Rubenstein shifts to Nominating/Gov., while facing a $950M patent settlement payment by July 8 (potentially $2.25B total). It also won an EU RSV supply deal and drew mixed analyst targets.
Previous Week Recap
- Moderna Board Adds Michael McDonnell: Moderna (MRNA) added Michael McDonnell to its board and Audit Committee on July 8, 2026. McDonnell is ex-Biogen CFO and sits on Merit Medical and Baxter boards. Rubenstein moved to Nominating/Gov.
- Global Patent Settlement With Arbutus: Moderna (MRNA) will pay $950M by July 8 under a global patent settlement over lipid nanoparticle tech for its COVID-19 vaccine; total payout could reach $2.25B, with Arbutus receiving about $179M.
- EU Procures RSV Vaccine Doses: Moderna won an EU procurement to supply up to 24M doses of RSV vaccine mRESVIA to six countries over up to four years. Product: single-dose prefilled syringe, EU-authorized for adults.
- Moderna Analyst Price Target Updates: Broker updates on Moderna (MRNA): BofA keeps Underweight, raises target to $38; RBC lifts target to $45; Morgan Stanley raises to $39. Analysts cite muted Q2, data risk and pipeline progress.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.